Recent advancements in genomic platforms and data repositories, such as the GuardantINFORMTM database17, which is a comprehensive and validated resource of genomic data obtained through non-invasive liquid biopsies from patients with advanced solid tumors, now offer fresh opportunities to more thoroughly investigate the prevalence and distribution of BRAF mutations (and other genomic alterations) in cancers. Here, BRAF is linked to cancer.